Stem cell technology developer Cellular Dynamics said Wednesday it will collaborate with the nonprofit Jain Foundation to create induced pluripotent stem cell lines from patients with certain genetic muscular dystrophies in an effort to find stem cell-based therapies for these disorders.
Unilife is at it again. This time it's Novartis signing a deal with the injectable technology provider, adding to Unilife's impressive list of recent agreements with top pharmaceutical companies Sanofi, MedImmune and Hikma.
A little more than two months after GlaxoSmithKline abandoned its $1.5 billion partnership on ChemoCentryx's lead drug, the Crohn's drug vercirnon, scrapping three late-stage studies after the first Phase III flopped, the biotech says that GSK has begged off pursuing a follow-up anti-inflammatory program and returned another drug--CCX354--licensed out four years ago.
Switzerland's Molecular Partners is convinced that it has created a better delivery vehicle for cancer drugs, and Roche is promising to pay up to a billion dollars-plus to see if they're right.
Celgene helped seal its reputation as one of the boldest dealmakers in biotech today, putting up $177.25 million in an upfront fee and equity stake while committing to more than $3 billion in milestones to partner on a slate of cancer stem cell programs in development at OncoMed.
The transactional model that once accounted for all CRO business is rapidly losing steam, Parexel International tells Outsourcing-Pharma, as Big Pharma sponsors recognize the benefits of deeper-seated strategic partnerships
Contract developer Almac has signed a deal to license its technology to Genomic Health for breast cancer diagnostics, reaping $9 million with the chance for a bigger payday down the road.
Fresh off a $25 million IPO, Evoke is riding into Phase III with its gastroparesis-treating nasal spray, and now the biotech has recruited SynteractHCR to serve as its go-to CRO for the late-stage effort.
At a time when its Big Pharma peers have sold noncore assets, Sanofi has diversified, with multibillion-dollar acquisitions of Genzyme and Merial adding biotech and animal health assets, respectively. Now, CEO Chris Viehbacher is looking for smaller, bolt-on deals to boost the vaccine business.
Regulus Therapeutics has partnered up with Biogen Idec to identify microRNA biomarkers in the blood of patients with multiple sclerosis, and the California biotech has charted some progress, pocketing a milestone payment and moving toward companion diagnostic development.